10.76
0.09 (0.84%)
Penutupan Terdahulu | 10.67 |
Buka | 10.75 |
Jumlah Dagangan | 3,767,234 |
Purata Dagangan (3B) | 6,679,614 |
Modal Pasaran | 7,677,787,136 |
Harga / Jualan (P/S) | 67.51 |
Harga / Buku (P/B) | 1.49 |
Julat 52 Minggu | |
Tarikh Pendapatan | 29 May 2025 |
Margin Keuntungan | -95.14% |
Margin Operasi (TTM) | -2,921.72% |
EPS Cair (TTM) | -1.00 |
Pertumbuhan Hasil Suku Tahunan (YOY) | -42.10% |
Pertumbuhan Pendapatan Suku Tahunan (YOY) | -96.70% |
Jumlah Hutang/Ekuiti (D/E MRQ) | 1.81% |
Nisbah Semasa (MRQ) | 37.91 |
Aliran Tunai Operasi (OCF TTM) | -775.34 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | -654.62 M |
Pulangan Atas Aset (ROA TTM) | -11.62% |
Pulangan Atas Ekuiti (ROE TTM) | -14.64% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Biotechnology (US) | Menurun | Menurun |
Biotechnology (Global) | Menurun | Menurun | |
Stok | Roivant Sciences Ltd. | Bercampur | Bercampur |
AISkor Stockmoo
Konsensus Penganalisis | 1.5 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | 1.0 |
Purata Bergerak Teknikal | 0.0 |
Osilator Teknikal | 0.5 |
Purata | 0.75 |
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others. |
|
Sektor | Healthcare |
Industri | Biotechnology |
Gaya Pelaburan | Mid Growth |
% Dimiliki oleh Orang Dalam | 29.44% |
% Dimiliki oleh Institusi | 79.40% |
Julat 52 Minggu | ||
Median | 18.00 (67.29%) | |
Jumlah | 1 Beli |
Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
---|---|---|---|---|
HC Wainwright & Co. | 28 May 2025 | 18.00 (67.29%) | Beli | 10.62 |
21 Apr 2025 | 18.00 (67.29%) | Beli | 10.04 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |